Increased nerve growth factor mRNA in lateral calf skin biopsies from diabetic patients

Diabetic Medicine

Volumn 16, Issue 2, 1999, Pages 113-119

  Diemel, L T ^a   Cai, F ^a   Anand, P ^b   Warner, G ^b   Kopelman, P G ^b   Fernyhough, P ^c   Tomlinson, D R ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

cRT PCR; Diabetes mellitus; Human; Nerve growth factor; Neuropathy; Neurotrophin

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC NEUROPATHY; FEMALE; HEAT SENSITIVITY; HUMAN; MALE; NERVE FIBER; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SKIN BIOPSY;

EID: 0032726717     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00035.x     Document Type: Article

References (46)

1. 1 Shelton DL, Reichardt LF. Expression of the beta nerve growth factor gene correlates with the density of sympathetic innervation in effector organs. Proc Natl Acad Sci USA 1984; 81: 7951-7955.
2. 2 Davies AM. Nerve growth factor synthesis and nerve growth factor receptor expression in neural development. Int Rev Cytol 1991; 128: 109-138.
3. 3 Dreyfus CF. Effects of nerve growth factor on cholinergic brain neurons. Trends Pharmacol Sci 1989; 10: 145-149.
4. 4 Hellweg R, Hartung H-D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990; 26: 258-267.
5. 5 Brewster WJ, Fernyhough P, Diemel LT, Mohiuddin L, Tomlinson DR. Diabetic neuropathy, nerve growth factor and other neurotrophic factors. Trends Neurosci 1994; 17: 321-325.
6. 6 Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Deficits in sciatic nerve neuropeptide content coincide with a reduction in target tissue nerve growth factor mRNA in streptozotocin-diabetic rats; effects of insulin treatment. Neuroscience 1994; 62: 337-344.
7. 7 Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR. Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 1995; 7: 1107-1110.
8. 8 Fernyhough P, Diemel LT, Brewster WJ, Tomlinson DR. Altered neurotrophin mRNA in peripheral nerve and skeletal muscle of experimentally diabetic rats. J Neurochem 1995; 64: 1231-1237.
9. NGFR. Mol Brain Res 1996; 37: 166-174.
10. 75LNTR protein in lumbar dorsal root ganglia. Mol Brain Res 1997; 51: 82-90.
11. 11 Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994; 634: 7-12.
12. 12 Diemel LT, Brewster WJ, Fernyhough P, Tomlinson DR. Expression of neuropeptides in experimental diabetes; effects of treatment with nerve growth factor or brain-derived neurotrophic factor. Mol Brain Res 1994; 21: 171-175.
13. 13 Verge VM, Riopelle RJ, Richardson PM. Nerve growth factor receptors on normal and injured sensory neurons. J Neurosci 1989; 9: 914-922.
14. 14 Dyck PJ. Nerve growth factor and diabetic neuropathy. Lancet 1996; 348: 1044-1045.
15. 15 Dyck PJ, Peroutka S, Rask C, Burton E, Baker MK, Lehman KA et al. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 1997; 48: 501-505.
16. 16 Anand P, Terenghi G, Warner G, Kopelman PG, Williams-Chestnut RE, Sinicropi DV. The role of endogenous nerve growth factor in human diabetic neuropathy. Nature Med 1996; 2: 703-707.
17. 17 Fruhstorfer H, Lindblom U, Schmidt WC. Method for quantitative estimation of thermal thresholds in patients. J Neurol Neurosurg Psychiatry 1976; 39: 1071-1075.
18. 18 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
19. 19 Anand P, Foley P, Navsaria HA, Sinicropi D, Williams-Chestnut RE, Leigh IM. Nerve growth factor levels in cultured human skin cells: Effect of gestation and viral transformation. Neurosci Lett 1995; 184: 157-160.
20. 20 Heumann R, Korsching S, Bandtlow CE, Thoenen H. Changes of nerve growth factor synthesis in non-neuronal cells in response to sciatic nerve transection. J Cell Biol 1987; 104: 1623-1631.
21. 21 Ullrich A, Gray A, Berman C, Dull TJ. Human β-nerve growth factor gene sequence highly homologous to that of mouse. Nature 1983; 303: 821-825.
22. 22 Cartwright M, Mikheev AM, Heinrich G. Expression of neurotrophin genes in human fibroblasts: Differential regulation of the brain-derived neurotrophic factor gene. Int J Dev Neurosci 1994; 12: 685-693.
23. 23 Celi FS, Zenilman ME, Shuldiner AR. A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res 1993; 21: 1047.
24. 24 Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 1987; 155: 335-350.
25. 25 Stoflet ES, Koeberl DD, Sarkar G, Sommer SS. Genomic amplification with transcript sequencing. Science 1988; 239: 491-494.
26. 26 Kain KC, Orlandi PA, Lanar DE. Universal promoter for gene expression without cloning: expression-PCR. Biotechniques 1991; 10: 366-374.
27. 27 Amand DS, Pottage C, Henry P, Fahnestock M. Method for quantitation of low-abundance nerve growth factor mRNA expression in human nervous tissue using competitive reverse transcription polymerase chain reaction. DNA Cell Biol 1996; 15: 415-422.
28. 28 Moretto G, Xu RY, Walker DG, Kim SU. Co-expression of mRNA for neurotrophic factors in human neurons and glial cells in culture. J Neuropathol Exp Neurol 1994; 53: 78-85.
29. 29 Kuroda T, Ueda M, Nakano M, Saeki M. Altered production of nerve growth factor in aganglionic intestines. J Pediatr Surg 1994; 29: 288-293.
30. 30 Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in streptozotocin-diabetic rats. Diabetes 1981; 30: 797-803.
31. 125I]nerve growth factor in ileal mesenteric nerves in vitro: effect of streptozotocin diabetes. Brain Res 1986; 378: 325-336.
32. 32 Hellweg R, Raivich G, Hartung H-D, Hock C, Kreutzberg GW. Axonal transport of endogenous nerve growth factor (NGF) and NGF receptor in experimental diabetic neuropathy. Exp Neurol 1994; 130: 24-30.
33. 33 Mearow KM, Kril Y, Diamond J. Increased NGF mRNA expression in denervated rat skin. Neuroreport 1993; 4: 351-354.
34. 34 Aloe L, Tuveri MA, Carcassi U, Levi-Montalcini R. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum 1992; 35: 351-355.
35. 35 Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 1995; 115: 1265-1275.
36. 36 Davis BM, Lewin GR, Mendell LM, Jones ME, Albers KM. Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. Neuroscience 1993; 56: 789-792.
37. 37 Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci 1993; 16: 353-359.
38. 38 Malcangio M, Garrett NE, Tomlinson DR. Nerve growth factor treatment increases stimulus-evoked release of sensory neuropeptides in the spinal cord. Eur J Neurosci 1997; 9: 1101-1104.
39. 39 Malcangio M, Garrett NE, Cruwys SC, Tomlinson DR. Nerve growth factor and neurotrophin-3 induced changes in nociceptive threshold and the release of substance P from the rat isolated spinal cord. J Neurosci 1997; 17: 8459-8467.
40. 40 Boulton AJM, Ward JD. Diabetic neuropathies and pain. Clin Endocrinol Metab 1986; 15: 917-931.
41. 41 Llewelyn JG, Thomas PK, Fonseca VA, King RHM, Dandona P. Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol 1986; 72: 157-163.
42. 42 Ross DR, Varipapa RJ. Treatment of painful diabetic neuropathy with topical capsaicin. New Eng J Med 1989; 321: 474-475.
43. 43 The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin: a multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991; 151: 2225-2229.
44. 44 Tandan R, Lewis GA, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Effect on sensory function. Diabetes Care 1992; 15: 15-18.
45. 45 Pfeifer MA, Ross DR, Schrage JP, Gelber DA, Schumer MP, Grain GM et al. A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 1993; 16: 1103-1115.
46. 46 Tsigos C, Diemel LT, White A, Tomlinson DR, Young RJ. Cerebrospinal fluid levels of substance P and calcitonin gene-related peptide: correlation with sural nerve levels and neuropathic signs in sensory diabetic neuropathy. Clin Sci 1993; 84: 305-311.